REVIEW

Recent advances in microbial fermentation for dairy and health [version 1; peer review: 3 approved]

Daragh Hill ^{1-3*}, Ivan Sugrue ^{1,2,4*}, Elke Arendt^{2,3}, Colin Hill^{2,4}, Catherine Stanton^{1,2}, R Paul Ross^{2,5}

¹Department of Biosciences, Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland

²APC Microbiome Institute, University College Cork, Cork, Ireland

³The School of Food and Nutritional Sciences, University College Cork, Cork, Ireland

⁴School of Microbiology, University College Cork, Cork, Ireland

⁵College of Science Engineering and Food Science, University College Cork, Cork, Ireland

* Equal contributors

V1 First published: 26 May 2017, 6(F1000 Faculty Rev):751
<https://doi.org/10.12688/f1000research.10896.1>

Latest published: 26 May 2017, 6(F1000 Faculty Rev):751
<https://doi.org/10.12688/f1000research.10896.1>

Abstract

Microbial fermentation has been used historically for the preservation of foods, the health benefits of which have since come to light. Early dairy fermentations depended on the spontaneous activity of the indigenous microbiota of the milk. Modern fermentations rely on defined starter cultures with desirable characteristics to ensure consistency and commercial viability. The selection of defined starters depends on specific phenotypes that benefit the product by guaranteeing shelf life and ensuring safety, texture, and flavour. Lactic acid bacteria can produce a number of bioactive metabolites during fermentation, such as bacteriocins, biogenic amines, exopolysaccharides, and proteolytically released peptides, among others. Prebiotics are added to food fermentations to improve the performance of probiotics. It has also been found that prebiotics fermented in the gut can have benefits that go beyond helping probiotic growth. Studies are now looking at how the fermentation of prebiotics such as fructo-oligosaccharides can help in the prevention of diseases such as osteoporosis, obesity, and colorectal cancer. The potential to prevent or even treat disease through the fermentation of food is a medically and commercially attractive goal and is showing increasing promise. However, the stringent regulation of probiotics is beginning to detrimentally affect the field and limit their application.

Keywords

microbial fermentation, prebiotic, fermented dairy product

Open Peer Review

Approval Status

	1	2	3
version 1 26 May 2017			

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Willem M de Vos**, Wageningen University, Wageningen, The Netherlands
2. **Pratyoosh Shukla**, Maharishi Dayanand University, Rohtak, India
3. **Miguel A. Alvarez**, IPLA-CSIC, Paseo Rio Linares s/n, Spain

Any comments on the article can be found at the end of the article.

Corresponding author: R Paul Ross (p.ross@ucc.ie)

Competing interests: The authors declare that they have no competing interests.

Grant information: DH and IS are in receipt of Teagasc Walsh Fellowships. The financial support of the following is gratefully acknowledged: JPI Food Processing for Health funded 'Longlife' and Science Foundation Ireland (SFI) under Grant Number SFI/12/RC/2273 in the APC Microbiome Institute.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Hill D *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Hill D, Sugrue I, Arendt E *et al.* **Recent advances in microbial fermentation for dairy and health [version 1; peer review: 3 approved]** F1000Research 2017, 6(F1000 Faculty Rev):751 <https://doi.org/10.12688/f1000research.10896.1>

First published: 26 May 2017, 6(F1000 Faculty Rev):751 <https://doi.org/10.12688/f1000research.10896.1>

Introduction

The fermentation of food by microbes has been employed for millennia as a process to ensure extended shelf life and improve the functionality, texture, and flavour of food products. The first evidence of dairy fermentation exists from approximately 7,000 years ago, where early Europeans are thought to have produced cheese¹. Methods have evolved from spontaneous fermentation by the indigenous microbial population to pre-selection of starter cultures with known attributes. Lactic acid bacteria (LAB) are the major bacteria used in food fermentations worldwide. LAB consist of a myriad of genera including, but not limited to, *Lactobacillus*, *Lactococcus*, *Streptococcus*, *Leuconostoc*, *Pediococcus*, and *Enterococcus*. Though the LAB are a diverse group of bacteria, many species enjoy historical “generally regarded as safe” (GRAS) and “qualified presumption of safety” (QPS) status by the Food and Drug Administration (FDA) and European Food Safety Authority (EFSA), respectively². LAB fermentation has long been recognised to confer beneficial effects on human health through the modulation of the intestinal microbiota. These either directly or indirectly affect the host microbiota, which in turn can lead to an effect on health. The use of these bacteria in fermentations to produce functional foods has greatly increased in recent years. Consumption of fermented foods has been associated with a range of health benefits from disease prevention to enhancing the bioregulation of behavioural issues such as stress and anxiety^{3–5}.

While the consumption of traditional fermented foods in cultures around the world is believed to have beneficial effects, not all of these foods have been subjected to appropriate trials in which these beliefs could be credited or discredited. The benefits of fermented

dairy products are being researched extensively in parts of the world, but other ethnic fermentations are also beginning to be studied in more detail⁶. These traditionally fermented foods use uncharacterised starter cultures that could possess novel properties or be useful in other fermentations, some of which will be discussed in more detail later^{6–8}. The potential application of microbial fermentation is enormous both in health and in biotechnology and will be an important area of research and production in the coming decades⁹. Yeasts and moulds are also prominent fermenting organisms in alcoholic and certain cheese fermentations. The focus of this review is to look at advances in the past three years in the field of microbial fermentation with a focus on food and added health benefits of fermentation, including extraneous commercial and legislative factors impacting the field (Figure 1).

Fermentation starter cultures and by-products of fermentation

Starter cultures, which carry out the fermentation process, are used to ensure consistency in commercial products by using known species with desirable traits, such as a high rate of acidification through the production of lactic acid and/or the secretion of secondary metabolites into the fermentate matrix (Figure 2). Novel starter cultures are continually in demand for the development of new commercial products along with greater characterisation of those currently in use to ensure safe and functional products. There are many positive and negative factors that impact the selection of starter cultures in dairy fermentations, such as a history of safe use, acidification rate during fermentation, exopolysaccharide production¹⁰, proteolytic activity, particularly during cheese production, and the generation of bioactive metabolites and peptides^{11,12}.

Figure 1. Schematic representing the relationships among fermenting microbes, fermented dairy products, and the consumer.

Figure 2. Desirable and undesirable bioactive metabolites produced during fermentation which can impact choice of starter cultures. Fermentation starters can produce a number of desirable and undesirable bioactive metabolites. Biogenic amines (left) are an undesirable product in most fermentations due to their toxicity. Bioactive peptides (right) produced through enzymatic release are desirable by-products due to positive biological activity. Bacteriocins (centre) are desirable as a known probiotic trait, but potentially undesirable in a starter culture due to possible impact on other fermenting cultures.

Bacteriocins

Bacteriocins are small ribosomally synthesised antimicrobial peptides against which the producer species is immune and which act against other bacteria in a bactericidal or bacteriostatic manner¹³. Great care must be taken with regard to bacteriocin production in starter cultures, as they may target other fermenting cultures or adjuncts; however, their ability to inhibit potential spoilage bacteria and pathogens can be of great use¹⁴. The identification of bacteriocinogenic strains has mostly relied on agar diffusion-based assays¹⁵. Increasing interest in bacteriocins as alternatives to antibiotics and chemical food preservatives has led to new methods for identifying bacteriocin producers. *In silico* screening using programs such as BAGEL¹⁶ and antiSMASH¹⁷ enables the discovery of new bacteriocin operons where whole genome data are available. Such methods avoid any potential problems with unsusceptible indicator strains¹⁸ and can allow for faster initial screening. Collins *et al.* (submitted, 2017) using an *in silico* screen of the genomes of 213 lactobacilli¹⁹ identified 11 bacteriocins, five of which were novel. Another *in silico* study which mined human gut microbiome sequence data found 74 bacteriocin gene clusters from 382 fully sequenced genomes²⁰. *In silico* screens such as these rely on previously described peptides or the identification of bacteriocin accessory genes, and as such it is unlikely that initial agar diffusion-based assays will be completely replaced with *in silico* screening. However, they may represent an opportunity to search for new bacteriocins in complex microbiotas such as those of a traditional fermented product.

Biogenic amines

Biogenic amines (BAs) are biologically active, low-molecular-weight organic bases produced mainly through the decarboxylation of certain amino acids, which can accumulate during fermentation. Traditionally, the presence of BAs in food products is associated with undesirable microbial activity, indicating food spoilage or defective manufacture²¹. Dairy products, in particular cheese, can accumulate high levels of BAs, mainly histamine and tyramine, which are known to be toxic^{22–24}, but as of yet legal limits have been set only for histamine in fish products²⁵. The accumulation of more than one kind of BA in products is of particular concern owing to their synergistic toxicity at dietary concentrations, which has recently been demonstrated with intestinal cells *in vitro*²⁶. BAs are detected in dairy products by the chromatographic detection of BA compounds or through the detection of BA-producer organisms using PCR-based methods, which correlate with HPLC results²⁷. In a recent study, levels of tyramine in a model cheese were reduced by 85% through the use of a bacteriophage to limit the population of BA-producing bacteria²⁸. Pre-selection of starter cultures lacking BA genes in the future may be necessary to avoid unwanted build-up of BA compounds and continued avoidance of contamination, which is known to occur during post-ripening processing^{29,30}.

Bioactive peptides

Bioactive peptides are encrypted in larger proteins and, when released after proteolysis, have been associated with health promotion through a number of mechanisms such as inhibition of

angiotensin 1-converting enzyme (ACE) activity, antithrombotic activity, antihypertensive activity, antioxidant activity, immunomodulation, apoptosis modulation, and by opioid and anti-opioid activities^{11,31}. LAB possess a myriad of proteases and peptidases that can release encrypted peptides during milk fermentation³² or following the ingestion of fermented products containing LAB in the intestinal lumen. In recent years, potential anticarcinogenic peptides have been found encrypted in bovine milk casein and whey proteins, including the previously known cationic lactoferricin³³. The known cancer-preventative peptide lunasin has been found to be proteolytically released during sourdough fermentation by LAB³⁴. Further research has subsequently revealed increased protease resistance during *in vitro* gastrointestinal transit in the presence of naturally occurring protease inhibitors to allow lunasin to reach the large intestine³⁵. Another recent study has found that the administration of milk fermented by a probiotic *Lactobacillus casei* strain modulated the immune response against a breast cancer tumour in a mouse model, with delayed or blocked tumour development in the fermented-milk-fed group as compared with unfermented milk as a control³⁶. The mechanism of action has not yet been elucidated, and studies of a similar nature have not yet passed the animal trial preclinical stages of investigation.

Ethnic fermented milk products

There is increasing interest in novel LAB strains isolated from ethnic fermented milk products, which would have been part of the autochthonous fermenting microbiota. Products such as matsoni, a fermented milk product of Armenian origin, and kule naoto, the traditional fermented milk product of the Maasai in Kenya, are having their previously undescribed microbiotas characterised using sequencing-based analysis^{37,38}. Indeed, such products may be of great value: for example shubat, a probiotic fermented camel milk of Kazakh origin, has recently been found to demonstrate positive hypoglycaemic activity in type 2 diabetic rats³⁹, and the indigenous Indian fermented beverage Raabadi has been investigated as a source of probiotic hypocholesterolaemic lactobacilli⁴⁰. However, a study of mursik, a milk product from Kenya that is traditionally fermented in a gourd, has been suggested as a possible etiological factor for oesophageal cancer because of high levels of ethanol and acetaldehyde present post fermentation⁴¹. This is in stark contrast to the health claims made for most commercial fermented dairy products that indicate the benefits of using safe, known starter cultures.

Prebiotics

In 2008, prebiotics were defined by the International Scientific Association for Probiotics and Prebiotics (ISAPP) as “a selectively fermented ingredient that results in specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring benefit(s) upon host health”⁴², a definition that is currently being further revised by ISAPP. Prebiotics are fermented by the gastrointestinal microbiota and contribute to healthy modulation of the gut⁴³. The ingestion of specific prebiotics has been shown to increase antibacterial capabilities of a probiotic strain⁴⁴. Synbiotics are a relatively new area that involve a combination of probiotic and prebiotic in one product; the prebiotic is intended to improve the survival/growth/performance of the probiotic or other beneficial bacteria in the colon, which in turn has beneficial health effects on the host⁴⁵.

Currently, research is being conducted on the role of the gut microbiota in the development of cancer, with a focus on colorectal cancer⁴⁶. While this research is in its early stage, there is evidence for the use of probiotics, prebiotics, and synbiotics in the treatment or prevention of this disease. There is potential for these to act as anticarcinogens or antimutagenic agents through diet-based interventions. More detailed analysis could lead to huge strides in the prevention of cancer, but as of yet the field is open to new research⁴⁷.

Health-focused research

Research into the use of fermented foods as a potential approach to fight disease is growing, but it must be appreciated that many of these functional foods are intended to prevent disease onset, or alleviate symptoms, and not necessarily act as a curative agent⁴⁸. This increases the burden of proof on the researcher to prove that the fermentation of the prebiotic was indeed the reason the host remained healthy. Modulation of the gut microbiota is the focus of many studies relating microbial fermentation to measureable health benefits. One emerging area of study using microbial fermentation is in osteoporosis. Osteoporosis is common in postmenopausal women and the elderly and presents itself as weakened bones prone to breaks or fractures due to poor calcium absorption⁴. The consumption of a prebiotic fructo-oligosaccharide (FOS) has the potential to be a preventative method for osteoporosis⁴⁹. The prebiotic is fermented in the gut, causing a drop in the pH of the lumen to such an extent that previously insoluble calcium phosphate will dissolve. This plays a beneficial role in bone mineral density⁵⁰. The fermentation of FOS releases short-chain fatty acids and lactic acid, which cause the drop in pH. This dissolved calcium results in an increase in passive diffusion; thus, it could help to treat, or even potentially prevent, the onset of osteoporosis.

Obesity is a global issue and has generated much interest in whether and how our gut bacteria could be a contributing factor in the development of this complex syndrome. On-going studies into the gut microbiota are aimed at identifying whether a specific bacterium or bacterial group could be contributing to obesity⁵¹. While this is an emerging area of research, there are exciting developments on how to potentially fight this syndrome through the modulation of the gut microbiota⁵². The so-called “obese microbiota profile” can be characterised as a decreased Bacteroidetes/Firmicutes ratio in individuals⁵¹. One study looked at the administration of prebiotics such as FOS as a potential method of reducing the likelihood of obesity by increasing the levels of “lean microbiota” through fermentation of the prebiotic in the gut. This in turn led to a decrease in the permeability of the intestine with improved tight junction integrity. While this is in early stages of research, it does present a potentially new method by which obesity could be treated through microbial fermentation within the gut⁵³. This area of research has great potential medically and commercially⁵⁴.

Bacteriocins, as discussed previously, are antimicrobial peptides that target and kill other bacteria and that could potentially be utilised as an anti-obesity tool. If specific strains that are contributing to obesity are identified, then modulation of the gut microbiota, through introduction of specific bacteriocins or bacteriocin producers has the potential to reduce the risk of obesity. Likewise, specific bacteriophages could be used to target such strains.

Current evidence supports the notion that microbes in the gut could be a contributing factor to mental disorders through the brain–gut axis⁵⁵. Psychobiotics are an emerging area of study on the role of the microbiota in brain health. A psychobiotic is a bacteria that, when ingested in adequate amounts, can have a positive mental health benefit⁵⁶. The permeability of the intestinal barrier can be compromised by the westernised diet of processed foods and carbonated beverages. The bacteria present in our gut are capable of producing neurotransmitters through the metabolism of indigestible fibres; these include dopamine, noradrenalin, GABA, and acetylcholine⁵⁷. The consumption of probiotics in fermented foods could have a positive influence on maintaining the intestinal barrier and preventing chronic inflammation. Dietary interventions in adolescents of more fermented foods containing beneficial brain bacteria could help prevent the onset of depression and anxiety, among other mental health issues, which are becoming more prevalent.

National recommendations

Fermented foods have been consumed worldwide for thousands of years before any direct health benefits were truly understood. While the demand from consumers for functional foods is growing, the national recommendations are not following suit. Now that the mechanisms by which these fermentations can beneficially affect human health are beginning to be elucidated, food guidelines around the world are slowly beginning to recommend their consumption. This inclusion is not universal, despite historical use and clinical trials proving the benefits of these fermented products in the diet. Given the strong tradition of fermented foods in Asia, it is somewhat surprising that they are not specifically included in food guidelines, albeit the Chinese Nutrition Society suggests the consumption of yogurt for those who do not tolerate lactose well.

There is a high incidence of lactose intolerance in Asian countries, and there are clinically proven studies that show the inclusion of fermented dairy foods can help to alleviate the symptoms of intolerance⁵⁸. Japanese authorities list fermented foods in the Food of Specified Health Use (FOSHU) category, and in India the guidelines specifically encourage the consumption of fermented foods. The Indian guide highlights specifically that pregnant women should consider including more fermented foods in their diet owing to the increased bioavailability of iron that is associated with these foods.

Regulation of fermented dairy products

The regulation surrounding microbial fermentations in the food industry is beginning to have a detrimental effect on the industry as a whole. For example, there is currently no legal definition for the term “probiotics”; until scientific, legal, and industrial teams are all working together under one solid definition, the term “probiotics” will begin to lose its meaning. Along with this, the general community are losing confidence in the benefits of fermented dairy products that are supplemented with probiotic/prebiotics. Since December 2012, in Europe, labelling of a probiotic was banned along with the use of health claims in any product without receiving approval from EFSA, which has yet to approve any probiotic health claim. This is despite the numerous clinical trials proving the benefits of probiotic yogurts in health. This change has led to consumer confusion as to

whether or not the claims were ever true. It is essential that labelling of fermented food products with clinically proven health benefits is permitted to allow industry to begin to profit from funding these trials, or they will begin to invest in marketing strategies rather than the much-needed research⁴². The International Dairy Federation (IDF) represents the dairy sector at relevant codex meetings regarding the international standards for dairy products⁵⁹. The IDF are currently involved in investigating product labelling with regard to nutritional information and health claims and how these affect the consumer’s choice of different products⁶⁰. These studies will hopefully lead to a change in labelling laws to allow for clinically proven health claims to be present on fermented dairy products.

Conclusion

Microbial fermentation holds the key to some extremely complex interactions between bacterial species and the food matrix they are fermenting. The studies highlighted in this review show the potential of utilising these microbial fermentations in a more knowledge-based fashion than that of the past. With regard to microbial fermentation in food, this represents an area with potential well beyond the extension of shelf life. The work in these areas is continuing and, with the help of better regulation, could lead to exciting new discoveries on managing disease symptoms through food. Though fermented products have long been associated with health promotion, the lack of regulation has been a confounding factor in consumer attitudes. Indeed, other legislation must be put in place in the near future for harmful levels of BAs in fermented dairy products, given that at present no upper limit for potentially toxic levels of histamine and tyramine are available. The search for probiotics is on-going using both genetic and traditional screening methods^{61,62}. Probiotics have a bright future in the area of supplemented fermented foods for health promotion.

There have been numerous advances in fermented products, the microbes which produce them, and fermentable polysaccharides in recent years. With public opinion shifting towards healthier lifestyles and viewing chemical preservatives in a negative light, fermented products show great commercial promise. New starter cultures are being identified using more sophisticated methods to ensure their effectiveness and viability. *In silico*-based methods and research in the health-promoting activities of LAB in fermentates are on the rise, along with the characterisation of traditional products that have been associated with good health.

Competing interests

The authors declare that they have no competing interests.

Grant information

DH and IS are in receipt of Teagasc Walsh Fellowships. The financial support of the following is gratefully acknowledged: JPI Food Processing for Health funded ‘Longlife’ and Science Foundation Ireland (SFI) under Grant Number SFI/12/RC/2273 in the APC Microbiome Institute.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Salque M, Bogucki PI, Pyzel J, *et al.*: **Earliest evidence for cheese making in the sixth millennium BC in northern Europe.** *Nature*. 2013; **493**(7433): 522–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. EFSA Panel on Biological Hazards (BIOHAZ): **Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 4: Suitability of taxonomic units notified to EFSA until March 2016.** *EFSA Journal*. 2016; **14**(7): e04522.
[Publisher Full Text](#)
3. **F** Ejtahed HS, Soroush AR, Angoorani P, *et al.*: **Gut Microbiota as a Target in the Pathogenesis of Metabolic Disorders: A New Approach to Novel Therapeutic Agents.** *Horm Metab Res*. 2016; **48**(6): 349–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
4. **F** Martinez RC, Bedani R, Saad SM: **Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: an update for current perspectives and future challenges.** *Br J Nutr*. 2015; **114**(12): 1993–2015.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
5. Parvez S, Malik KA, Ah Kang S, *et al.*: **Probiotics and their fermented food products are beneficial for health.** *J Appl Microbiol*. 2006; **100**(6): 1171–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. **F** Owusu-Kwarteng J, Tano-Debrah K, Akabanda F, *et al.*: **Technological properties and probiotic potential of *Lactobacillus fermentum* strains isolated from West African fermented millet dough.** *BMC Microbiol*. 2015; **15**: 261.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
7. Ao X, Zhang X, Zhang X, *et al.*: **Identification of lactic acid bacteria in traditional fermented yak milk and evaluation of their application in fermented milk products.** *J Dairy Sci*. 2012; **95**(3): 1073–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. **F** Anandharaj M, Sivasankari B, Santhanakaruppu R, *et al.*: **Determining the probiotic potential of cholesterol-reducing *Lactobacillus* and *Weissella* strains isolated from gherkins (fermented cucumber) and south Indian fermented koozh.** *Res Microbiol*. 2015; **166**(5): 428–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
9. Abdel-Rahman MA, Tashiro Y, Sonomoto K: **Recent advances in lactic acid production by microbial fermentation processes.** *Biotechnol Adv*. 2013; **31**(6): 877–902.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Ryan PM, Ross RP, Fitzgerald GF, *et al.*: **Sugar-coated: exopolysaccharide producing lactic acid bacteria for food and human health applications.** *Food Funct*. 2015; **6**(3): 679–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Pessione E, Cirrincione S: **Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines.** *Front Microbiol*. 2016; **7**: 876.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Dobson A, Cotter PD, Ross RP, *et al.*: **Bacteriocin production: a probiotic trait?** *Appl Environ Microbiol*. 2012; **78**(1): 1–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Hegarty JW, Guinane CM, Ross RP, *et al.*: **Bacteriocin production: a relatively unharvested probiotic trait? [version 1; referees: 2 approved].** *F1000Res*. 2016; **5**: 2587.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Galvez A, Lopez RL, Abriouel H, *et al.*: **Application of bacteriocins in the control of foodborne pathogenic and spoilage bacteria.** *Crit Rev Biotechnol*. 2008; **28**(2): 125–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Wolf CE, Gibbons WR: **Improved method for quantification of the bacteriocin nisin.** *J Appl Bacteriol*. 1996; **80**(4): 453–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. van Heel AJ, de Jong A, Montalbán-López M, *et al.*: **BAGEL3: Automated identification of genes encoding bacteriocins and (non-)bactericidal posttranslationally modified peptides.** *Nucleic Acids Res*. 2013; **41**(Web Server issue): W448–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. **F** Blin K, Medema MH, Kottmann R, *et al.*: **The antiSMASH database, a comprehensive database of microbial secondary metabolite biosynthetic gene clusters.** *Nucleic Acids Res*. 2017; **45**(D1): D555–D559.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
18. Papagianni M, Avramidis N, Filioussis G, *et al.*: **Determination of bacteriocin activity with bioassays carried out on solid and liquid substrates: assessing the factor “indicator microorganism”.** *Microb Cell Fact*. 2006; **5**: 30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Collins F, O'Connor PM, Gómez-Sala B, *et al.*: **Bacteriocin gene-trait matching across the complete *Lactobacillus* pangenome.** *Sci Rep*. 2017; awaiting print.
20. Walsh CJ, Guinane CM, Hill C, *et al.*: **In silico identification of bacteriocin gene clusters in the gastrointestinal tract, based on the Human Microbiome Project's reference genome database.** *BMC Microbiol*. 2015; **15**: 183.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Linares DM, Martin MC, Ladero V, *et al.*: **Biogenic amines in dairy products.** *Crit Rev Food Sci Nutr*. 2011; **51**(7): 691–703.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. **F** Linares DM, del Rio B, Redruello B, *et al.*: **Comparative analysis of the in vitro cytotoxicity of the dietary biogenic amines tyramine and histamine.** *Food Chem*. 2016; **197**(Pt A): 658–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
23. EFSA Panel on Biological Hazards (BIOHAZ): **Scientific Opinion on risk based control of biogenic amine formation in fermented foods.** *EFSA Journal*. 2011; **9**(10): 2393.
[Publisher Full Text](#)
24. Ladero V, Cañedo E, Pérez M, *et al.*: **Multiplex qPCR for the detection and quantification of putrescine-producing lactic acid bacteria in dairy products.** *Food Control*. 2012; **27**(2): 307–13.
[Publisher Full Text](#)
25. Regulation EC: 2073/2005 of 15 November 2005 on microbiological criteria for foodstuffs. *Official Journal of the European Union*. 2005; **338**: 1–29.
[Reference Source](#)
26. **F** Del Rio B, Redruello B, Linares DM, *et al.*: **The dietary biogenic amines tyramine and histamine show synergistic toxicity towards intestinal cells in culture.** *Food Chem*. 2017; **218**: 249–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
27. Fernández M, Linares DM, Del Rio B, *et al.*: **HPLC quantification of biogenic amines in cheeses: correlation with PCR-detection of tyramine-producing microorganisms.** *J Dairy Res*. 2007; **74**(3): 276–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. **F** Ladero V, Gómez-Sordo C, Sánchez-Llana E, *et al.*: **Q69 (an *E. faecalis*-infecting Bacteriophage) As a Biocontrol Agent for Reducing Tyramine in Dairy Products.** *Front Microbiol*. 2016; **7**: 445.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
29. Ladero V, Fernández M, Alvarez MA: **Effect of post-ripening processing on the histamine and histamine-producing bacteria contents of different cheeses.** *Int Dairy J*. 2009; **19**(12): 759–62.
[Publisher Full Text](#)
30. **F** Diaz M, Del Rio B, Sanchez-Llana E, *et al.*: **Histamine-producing *Lactobacillus parabuchneri* strains isolated from grated cheese can form biofilms on stainless steel.** *Food Microbiol*. 2016; **59**: 85–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
31. Hayes M, Ross RP, Fitzgerald GF, *et al.*: **Putting microbes to work: dairy fermentation, cell factories and bioactive peptides. Part I: overview.** *Biotechnol J*. 2007; **2**(4): 426–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Savijoki K, Ingmer H, Varmanen P: **Proteolytic systems of lactic acid bacteria.** *Appl Microbiol Biotechnol*. 2006; **71**(4): 394–406.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Pepe G, Tenore GC, Mastrocinque R, *et al.*: **Potential anticarcinogenic peptides from bovine milk.** *J Amino Acids*. 2013; **2013**: 939804.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Rizzello CG, Nionelli L, Coda R, *et al.*: **Synthesis of the cancer preventive peptide lunasin by lactic acid bacteria during sourdough fermentation.** *Nutr Cancer*. 2012; **64**(1): 111–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. **F** Cruz-Huerta E, Fernández-Tomé S, Arques MC, *et al.*: **The protective role of the Bowman-Birk protease inhibitor in soybean lunasin digestion: the effect of released peptides on colon cancer growth.** *Food Funct*. 2015; **6**(8): 2626–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
36. **F** Aragón F, Carino S, Perdígón G, *et al.*: **The administration of milk fermented by the probiotic *Lactobacillus casei* CRL 431 exerts an immunomodulatory effect against a breast tumour in a mouse model.** *Immunobiology*. 2014; **219**(6): 457–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
37. **F** Bokulich NA, Amiranshvil L, Chitchyan K, *et al.*: **Microbial biogeography of the transnational fermented milk market.** *Food Microbiol*. 2015; **50**: 12–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
38. **F** Oguntuyinbo FA, Cho GS, Brinks E, *et al.*: **Draft Genome Sequence of *Lactobacillus plantarum* BFE 5092 Isolated from Maasai Fermented Milk.** *Genome Announc*. 2016; **4**(3): pii: e00481-16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
39. **F** Manaer T, Yu L, Zhang Y, *et al.*: **Anti-diabetic effects of shubat in type 2 diabetic rats induced by combination of high-glucose-fat diet and low-dose**

- streptozotocin. *J Ethnopharmacol.* 2015; **169**: 269–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
40. **F** Yadav R, Puniya AK, Shukla P: **Probiotic Properties of *Lactobacillus plantarum* RYPR1 from an Indigenous Fermented Beverage Raabadi.** *Front Microbiol.* 2016; **7**: 1683.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 41. Nieminen MT, Novak-Frazer L, Collins R, *et al.*: **Alcohol and acetaldehyde in African fermented milk *mursik*—a possible etiologic factor for high incidence of esophageal cancer in western Kenya.** *Cancer Epidemiol Biomarkers Prev.* 2013; **22**(1): 69–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. Hill C, Guarner F, Reid G, *et al.*: **Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic.** *Nat Rev Gastroenterol Hepatol.* 2014; **11**(8): 506–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Di Bartolomeo F, Startek JB, van den Ende W: **Prebiotics to fight diseases: reality or fiction?** *Phytother Res.* 2013; **27**(10): 1457–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. **F** Pranckutė R, Kaunietis A, Kuisienė N, *et al.*: **Combining prebiotics with probiotic bacteria can enhance bacterial growth and secretion of bacteriocins.** *Int J Biol Macromol.* 2016; **89**: 669–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 45. **F** Pranckute R, Kaunietis A, Kuisiene N, *et al.*: **Development of synbiotics with inulin, palatinose, alpha-cyclodextrin and probiotic bacteria.** *Pol J Microbiol.* 2014; **63**(1): 33–41.
[PubMed Abstract](#) | [F1000 Recommendation](#)
 46. **F** Ambalam P, Raman M, Purama RK, *et al.*: **Probiotics, prebiotics and colorectal cancer prevention.** *Best Pract Res Clin Gastroenterol.* 2016; **30**(1): 119–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 47. Raman M, Ambalam P, Kondepudi KK, *et al.*: **Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer.** *Gut Microbes.* 2013; **4**(3): 181–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. **F** Maldonado Galdeano C, Novotny Nuñez I, Carmuega E, *et al.*: **Role of probiotics and functional foods in health: gut immune stimulation by two probiotic strains and a potential probiotic yoghurt.** *Endocr Metab Immune Disord Drug Targets.* 2015; **15**(1): 37–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 49. **F** Belorkar SA, Gupta AK: **Oligosaccharides: a boon from nature's desk.** *AMB Express.* 2016; **6**(1): 82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 50. **F** Slevin MM, Allsopp PJ, Magee PJ, *et al.*: **Supplementation with calcium and short-chain fructo-oligosaccharides affects markers of bone turnover but not bone mineral density in postmenopausal women.** *J Nutr.* 2014; **144**(3): 297–304.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 51. **F** Compare D, Rocco A, Sanduzzi Zamparelli M, *et al.*: **The Gut Bacteria-Driven Obesity Development.** *Dig Dis.* 2016; **34**(3): 221–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 52. **F** Madjd A, Taylor MA, Mousavi N, *et al.*: **Comparison of the effect of daily consumption of probiotic compared with low-fat conventional yogurt on weight loss in healthy obese women following an energy-restricted diet: a randomized controlled trial.** *Am J Clin Nutr.* 2016; **103**(2): 323–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 53. Million M, Lagier JC, Yahav D, *et al.*: **Gut bacterial microbiota and obesity.** *Clin Microbiol Infect.* 2013; **19**(4): 305–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. **F** Chen Z, Guo L, Zhang Y, *et al.*: **Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.** *J Clin Invest.* 2014; **124**(8): 3391–406.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 55. **F** Jacka FN, Cherbuin N, Anstey KJ, *et al.*: **Does reverse causality explain the relationship between diet and depression?** *J Affect Disord.* 2015; **175**: 248–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 56. **F** Dinan TG, Cryan JF: **The Microbiome-Gut-Brain Axis in Health and Disease.** *Gastroenterol Clin North Am.* 2017; **46**(1): 77–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 57. **F** Sarkar A, Lehto SM, Harty S, *et al.*: **Psychobiotics and the Manipulation of Bacteria-Gut-Brain Signals.** *Trends Neurosci.* 2016; **39**(11): 763–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 58. Capurso L: **Probiotics and prebiotics and food intolerance.** *Allergy.* 2001; **56 Suppl 67**: 125–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. International Dairy Federation: **International Dairy Federation Annual report.** 2015/2016.
[Reference Source](#)
 60. Mayhew AJ, Lock K, Kelishadi R, *et al.*: **Nutrition labelling, marketing techniques, nutrition claims and health claims on chip and biscuit packages from sixteen countries.** *Public Health Nutr.* 2016; **19**(6): 998–1007.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. **F** Yadav R, Kumar V, Baweja M, *et al.*: **Gene editing and genetic engineering approaches for advanced probiotics: A Review.** *Crit Rev Food Sci Nutr.* 2017; **0**.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 62. **F** Yadav R, Singh PK, Shukla P: **Metabolic engineering for probiotics and their genome-wide expression profiling.** *Curr Protein Pept Sci.* 2016.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Miguel A. Alvarez**

Dairy Research Institute, IPLA-CSIC, Paseo Rio Linares s/n, 33300 Villaviciosa, Spain

Competing Interests: No competing interests were disclosed.

2. **Pratyosh Shukla**

Enzyme Technology and Protein Bioinformatics Laboratory, Department of Microbiology, Maharishi Dayanand University, Rohtak, Haryana, India

Competing Interests: No competing interests were disclosed.

3. **Willem M de Vos**

Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research